ArticleParkinsonism & related disorders2022
Imaging biomarkers for early multiple system atrophy.
Article in Parkinsonism & related disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Polysomnographic findings of multiple system atrophy: evidence from case-control studies.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2025Pooled it
- Astrocytic FABP5 drives non-cell-autonomous oligodendrocyte injury in multiple system atrophy by promoting TNF signaling and ferroptotic stress.Redox biology · 2026Article
- Integrated quantitative susceptibility mapping and radiomics for multiple system atrophy subtypes classification.Neuroradiology · 2026Article
- Multiparametric MRI and imaging transcriptomics reveal molecular and cellular correlates of neurodegeneration in experimental Parkinsonism.NPJ Parkinson's disease · 2026Article
- The role of neuro-imaging in multiple system atrophy.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Multiple System Atrophy Combined Outcome Assessment (MuSyCA): process, format, and validation plan.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2026Article
- Precise disease heterogeneity and progression quantification in MSA and Parkinson's disease using machine learning.Scientific reports · 2026Article
- Functional MRI in Multiple System Atrophy: A Promising Biomarker for Clinical Applications.Neuropsychiatric disease and treatment · 2026Review
- Disease Progression in Multiple System Atrophy: The ASPIRE Multi-Modal Biomarker Study.Annals of neurology · 2026Article
- The MSA Atrophy Index (MSA-AI): An Imaging Marker for Diagnosis and Clinical Progression in Multiple System Atrophy.Annals of clinical and translational neurology · 2025Article
- Trajectories of Pontine Volume in Patients with Multiple System Atrophy.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- White Matter Abnormalities Track Disease Progression in Multiple System Atrophy.Movement disorders clinical practice · 2024Article
- Neuroradiological findings in GAA-medRxiv : the preprint server for health sciences · 2024Article
- Comparison of spontaneous brain activity in distinguishing parkinsonian variant of multiple system atrophy from Parkinson's disease at an early stage.Frontiers in aging neuroscience · 2024Article
- Combined regional T1w/T2w ratio and voxel-based morphometry in multiple system atrophy: A follow-up study.Frontiers in neurology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo systematically evaluate structural MRI and diffusion MRI features for cross-sectional discrimination and tracking of longitudinal disease progression in early multiple system atrophy (MSA).
methodsIn a prospective, longitudinal study of synucleinopathies with imaging on 14 controls and 29 MSA patients recruited at an early disease stage (15 predominant cerebellar ataxia subtype or MSA-C and 14 predominant parkinsonism subtype or MSA-P), we computed regional morphometric and diffusion MRI features. We identified morphometric features by ranking them based on their ability to distinguish MSA-C from controls and MSA-P from controls and evaluated diffusion changes in these regions. For the top performing regions, we evaluated their utility for tracking longitudinal disease progression using imaging from 12-month follow-up and computed sample size estimates for a hypothetical clinical trial in MSA. We also computed these selected morphometric features in an independent validation dataset.
resultsWe found that morphometric changes in the cerebellar white matter, brainstem, and pons can separate early MSA-C patients from controls both cross-sectionally and longitudinally (p < 0.01). The putamen and striatum, though useful for separating early MSA-P patients from control subjects at baseline, were not useful for tracking MSA disease progression. Cerebellum white matter diffusion changes aided in capturing early disease related degeneration in MSA.
interpretationRegardless of clinically predominant features at the time of MSA assessment, brainstem and cerebellar pathways progressively deteriorate with disease progression. Quantitative measurements of these regions are promising biomarkers for MSA diagnosis in early disease stage and potential surrogate markers for future MSA clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.